<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153094">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01985490</url>
  </required_header>
  <id_info>
    <org_study_id>2013-07-163</org_study_id>
    <nct_id>NCT01985490</nct_id>
  </id_info>
  <brief_title>Change in Foveal Avascular Zone After Removal of Epiretinal Membrane and Internal Limiting Membrane</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fovea is characterized by its vessel-free zone, called foveal avascular zone and it can be
      visualized by fluorescein angiography. Removal of epiretinal membrane and internal limiting
      membrane is frequently performed procedure and we suspected that these procedures may affect
      integrity of foveal avascular zone.

      The purpose of the present study is to evaluate the change of foveal avascular zone after
      removal of epiretinal membrane and internal limiting membrane
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>area of foveal avascular zone</measure>
    <time_frame>postoperative 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the change in area of foveal avascular zone at postoperative 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in visual acuity</measure>
    <time_frame>postoperative 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in macular thickness</measure>
    <time_frame>at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in metamorphopsia</measure>
    <time_frame>postoperative 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>epiretinal membrane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>epiretinal membrane and internal limiting membrane removal</intervention_name>
    <description>fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.</description>
    <arm_group_label>epiretinal membrane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  epiretinal membrane

        Exclusion Criteria:

          -  history of vitrectomy, intraocular surgery

          -  any macular disease other than epiretinal membrane

          -  media opacity obscuring the image of fluorescein angiography
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Se Woong Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Se Woong Kang, MD</last_name>
    <phone>82-2-3410-3562</phone>
    <email>swkang@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Woong Kang, MD</last_name>
      <phone>82-2-3410-3562</phone>
      <email>swkang@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Se Woong Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ga Eun Cho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>November 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epiretinal membrane</keyword>
  <keyword>foveal avascular zone</keyword>
  <keyword>internal limiting membrane</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
